Discover six hemophilia companies developing new treatments for the genetic bleeding disorder, from gene therapies to RNAi ...

If generative AI could contribute in the slightest to such discoveries—as has been promised since the start of the AI boom—where would the technology ... company pioneering AI-driven drug ...

The effectiveness of a drug can ... many factors contribute to these differences, such as genetics and diet, we believe that gut bacteria also play a key role,” Dr. Qihao Wu, assistant professor at ...

Technological advancements in cardiac ablation, including improvements in catheter designs, ablation energy sources such as radiofrequency and cryoablation, and the introduction of innovative mapping ...

Portal’s technology has a broad range of applications, from drug screening and discovery to advanced cell engineering for research and therapeutic purposes. Despite being only 2 years old, the company ...

According to statistics published by the World Health Organization (WHO) in 2025, cardiovascular diseases (CVDs) are the ...

NT219, a novel dual inhibitor of IRS1/2 and STAT3, is being evaluated in a Phase 2 study in patients with recurrent and/or ...

A new longevity report by Iris Ventures argues that people of all age groups are taking action, eating the rainbow and relying on vitamins, supplements and natural compounds to live longer and ...

Indegene Ltd (NSE:INDGN) reports a 9.6% revenue increase and a 100% dividend, while navigating client challenges and macroeconomic uncertainties.

Q1 2025 Earnings Call Transcript April 30, 2025 Tandem Diabetes Care, Inc. misses on earnings expectations. Reported EPS is $ ...

Hello, and welcome to the Third Quarter Fiscal Year 2025 Cardinal Health Incorporated Earnings Conference Call. My name is George, and I'll be the coordinator for today's event. Please note, this ...

The Global Enteral Feeding Devices Market has demonstrated significant growth, valued at $2,828.52 million in 2019. It is projected to expand to $4,426.54 million by 2027, with a ...